Compare · EW vs INGN
EW vs INGN
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Inogen Inc (INGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and INGN operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $52.30B, about 369.8x INGN ($141.4M).
- Over the past year, EW is up 11.0% and INGN is down 33.9% - EW leads by 44.9 points.
- EW has hit the wire 6 times in the past 4 weeks while INGN has been quiet.
- EW has more recent analyst coverage (25 ratings vs 11 for INGN).
- Company
- Edwards Lifesciences Corporation
- Inogen Inc
- Price
- $90.75+0.01%
- $5.35-0.37%
- Market cap
- $52.30B
- $141.4M
- 1M return
- +2.17%
- -20.39%
- 1Y return
- +11.02%
- -33.91%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 11
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Latest EW
- SVP, Corporate Controller Dahl Andrew M. sold $49,534 worth of shares (544 units at $91.06), decreasing direct ownership by 4% to 14,868 units (SEC Form 4)
- CVP, EMEACLA Bruls Annette sold $237,907 worth of shares (2,644 units at $89.98), decreasing direct ownership by 13% to 17,984 units (SEC Form 4)
- Edwards Lifesciences Corporation filed SEC Form 8-K: Leadership Update
- CVP, TMTT, Surgical & IHFM Chopra Daveen exercised 31,800 shares at a strike of $72.68 and sold $2,894,440 worth of shares (31,800 units at $91.02) (SEC Form 4)
- CVP, JAPAC Markowitz Wayne sold $113,417 worth of shares (1,240 units at $91.47), decreasing direct ownership by 6% to 20,294 units (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,967 worth of shares (619 units at $92.03) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Edwards Lifesciences Corporation
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- CVP, JAPAC Markowitz Wayne sold $12,588 worth of shares (146 units at $86.03), decreasing direct ownership by 0.67% to 21,534 units (SEC Form 4)
- CVP, JAPAC Markowitz Wayne exercised 9,628 shares at a strike of $74.02 and sold $818,958 worth of shares (9,628 units at $85.06) (SEC Form 4)
Latest INGN
- SEC Form 10-Q filed by Inogen Inc
- Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Inogen Announces Second Quarter 2026 Financial Results
- Smartbird Nominates Tech Industry Veterans Elizabeth Mora and Dan Kasun for Election to Its Board of Directors
- SEC Form S-8 filed by Inogen Inc
- Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026
- SEC Form 4 filed by EVP, COO Reding Andrew P.
- SEC Form 3 filed by new insider Reding Andrew P.
- EVP Entrprs Enblmnt, Ch HR Off Yi Boyer Jennifer M sold $72,146 worth of shares (10,938 units at $6.60) as part of a pre-agreed trading plan, decreasing direct ownership by 68% to 5,039 units (SEC Form 4)
- Inogen Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits